AstraZenecaAZN
Recorded

AstraZeneca 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 45 minParticipants22

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Joris SilonHead of Investor Relations

A warm welcome to AstraZeneca's nine-month and third quarter 2026 presentation conference call and webcast for investors and analysts. I'm Joris Silon, Head of Investor Relations, and before I hand over to Pascal and members of our executive team, I would like to cover some housekeeping items. All of the materials presented today are available on our AstraZeneca Investor Relations website. Next slide, please. This slide contains our forward-looking statements, including the safe harbor provisions, which I would encourage you to take the time to read. We will be making comments on our performance using constant exchange rates, or CER, for financial numbers and other non-GAAP measures. A non-GAAP to GAAP reconciliation is contained within the results announcement. All numbers quoted are in millions of U.S. dollars unless stated otherwise. Next slide, please. This slide shows our agenda for today's call.

Joris SilonHead of Investor Relations

Following our prepared remarks, we will open the line for questions, and as usual, we will try to address as many questions as we can during the allocated time. Please limit the number of questions you ask to allow others a fair chance to participate in the Q&A. With that, please advance to the next slide, and Pascal, over to you.

Pascal SoriotCEO

Thank you, Joris, and welcome, everybody. Next slide, please. I'm pleased to report that our strong growth momentum and pipeline delivery have continued through the first nine months of 2026. This reflects the progress we're making across our strategic priorities, and above all, the focus and the commitment of teams across our company. Total revenue grew 7% and core EPS increased 14%. Excluding Farxiga and Brilinta, total revenue grew 12%, demonstrating the underlying strength of our broad portfolio. Since our full-year results in February, we've announced positive results from 12 phase III programs, and we've achieved first approvals for four new medicines, including Adakama in the U.S. This brings our total number of approved new molecular entities to 14, as we progress towards our goal of delivering 20 new medicines by 2030.

Pascal SoriotCEO

We've also presented positive phase III data for three new molecular entities, tozorakimab in COPD, efzimfotase alfa in HPP, and Sone-Ve, our first wholly owned ADC, including claudin 18.2-positive gastric cancer. With commercial momentum continuing and a deep late-stage pipeline advancing, we are increasingly confident in our ability to deliver our 2030 ambition, as well as sustainable long-term growth through the next decade. Next slide, please. Our strong performance is underpinned by the breadth of our therapy areas and our geographical footprint. In the first nine months, oncology, rare disease, and R&I all delivered double-digit growth. Together, they more than offset the expected headwinds we've seen from the loss of exclusivity of Farxiga and Brilinta in CVRM. We've also delivered robust growth across the U.S., Europe, and the emerging markets outside of China. In China, growth continued to be impacted by volume-based procurement.

Pascal SoriotCEO

But excluding this impact, China grew 13%, with growth across all therapy areas. Next slide, please. Over the first 9 months of the year, we saw positive results from 12 important phase III programs. Let me say a couple of words about some of these. Tozorakimab has enormous potential, and we are now developing it beyond COPD. Volrustomig again is a blockbuster opportunity. I also want to come back on the Tagrisso franchise. A few years ago, we were told Tagrisso was going to be challenged by the launch of competitor regimens. Look at what we've done. The combination with Orpathys has the potential to drive both broader first-line use as well as longer Tagrisso-based treatment duration, keeping patients on Tagrisso rather than switching them off, and therefore protecting the franchise from newcomers. We have really made tremendous progress with Tagrisso.

Pascal SoriotCEO

VOLGA is another example of building the Imfinzi franchise. Lastly, efzimfotase alfa and Sone-Ve could both become $3 billion-$5 billion products, depending on the type of label we get. You can see that we have added quite a number of substantial opportunities to our growth potential. Together, this positive readout represents more than $10 billion in non-risk-adjusted peak year sales potential, maintaining the scale of opportunity we outlined at the start of the year. Importantly, with the positive data in hand, much of the risk behind these opportunities has now been removed. This shows the strength and diversification of our pipeline and underpins our confidence in achieving our $80 billion ambition by 2030. As I will show you next, the platforms and technologies we are investing in today position us to keep growing well beyond that. Next slide, please. This quarter, we announced an equity investment in Summit Therapeutics, together with clinical collaborations to combine ivonescimab with Sone-Ve and Datroway, and plans to broaden our collaborations further.

Pascal SoriotCEO

Under the terms of the agreement, each company will contribute their respective medicine for the planned combination trials and jointly contribute to trial costs. Ivo is the leading PD-1/VEGF bispecific, a class we expect to play a role in selected tumor types. It complements our own IO bispecifics, rilvegostomig and volrustomig, which we continue to progress at pace. This is an example of how we are maximizing the value of our rapidly growing ADC portfolio. We believe ADCs will become the backbone of treatment across tumor types, and this partnership gives flexibility to combine them with the optimal next-generation immuno-oncology partner for each setting.

Pascal SoriotCEO

This collaboration strengthens the core pillar of our oncology vision, building novel combinations, and is of strategic benefit to the companies involved. We look forward to updating you as these programs progress. Next slide, please. Turning now to the longer term, our ambition is to keep growing well past 2030, and that is why we are investing today in the technologies we believe will change how a wide range of diseases are treated in the future. Across five platforms, the first 9 months of 2026 have brought significant progress. Starting with weight management and cardiovascular risk factors, we expect the first phase III data for laroprovstat in the first half of 2027. We now have phase III trials ongoing for elecoglipron, and we've initiated phase III trials for our respective, our selective, sorry, amylin receptor agonist, lenbelintide. In ADCs and radioconjugates, progress has been strong.

Pascal SoriotCEO

Clarity-Gastric01 delivered an unprecedented overall survival benefit for sonesitatug vedotin second line and later gastric cancer. We expect the first phase III data for our second wholly owned ADC, puxitatug samrotecan, in the second half of 2027, and we initiated three phase III trials for torvutatug samrotecan this year. The Summit collaboration I described previously is another way we are maximizing the ADC opportunity. For our next generation immuno-oncology bispecifics, we now have 15 phase III trials across nine tumor types, six of which combine our bispecifics with our ADCs. We expect the first phase III readouts for rilvegostomig and volrustomig in the second half of 2027. Our cell therapy and T-cell engager portfolios are also advancing. We have three ongoing phase III trials of AZD0120 in multiple myeloma, and two phase III trials of surovatamig are progressing in B-cell lymphomas.

Pascal SoriotCEO

Both platforms have been extended into autoimmune diseases, with early trials underway, underscoring their broader therapeutic potential. Beyond these lead programs, we have four further clinical stage cell therapies and four additional T-cell engagers in early development, which will help us reach more patients across more disease areas. Together, these programs form a deep late-stage pipeline of multi-blockbuster opportunities that will underpin our next wave of growth. You can expect a steady flow of news, with more than 20 key phase III readouts planned for 2027. I will say more about this when I close. With that, I will hand over to Aradhana to take you through our financials. Please move to the next slide.

Aradhana SarinCFO

Thank you. Thank you, Pascal, and good morning, good afternoon, everyone.

Aradhana SarinCFO

As usual, I will start with our reported P&L. Next slide, please. As Pascal highlighted, we delivered continued top-line momentum in the first nine months of the year. Total revenue increased by 7%, with product revenue up 6%. Alliance revenue increased by 32%, driven by higher profit sales from our partnered medicines in Enhertu, Datroway, and Tezspire in markets where our partners record product sales. Next slide, please. Turning to the core P&L. Core gross margin was 83% in the first nine months. As we indicated previously, we expect gross margin in the second half to be below the first half, reflecting the seasonal demand profile of lower-margin medicines such as FluMist and Beyfortus. We also expect to see the usual year-end impact of hospital budget capping and NRDL stock compensation in China in the fourth quarter.

Aradhana SarinCFO

For the full year, we continue to expect core gross margins to be stable to slightly higher than in 2025. Core R&D expense increased by 5% year-to-date, reflecting continued investment in the pipeline. R&D represented 23% of total revenue in the first nine months, and we continue to expect it to be at the upper end of the low 20s percentage range for the full year. We are continuing to invest behind the opportunities that drive long-term growth, including bispecifics, cell therapies, and T-cell engagers, along with our ongoing investment in weight management and cardiovascular outcome trials. Core SG&A expense increased by 4% year-to-date. This reflects the investment behind the U.S. launch of Baxfendy, preparations for the anticipated launch of tozorakimab next year, and investment behind the launches of the 47 major market regulatory approvals received since the full year results in February.

Aradhana SarinCFO

Overall, core operating expenses increased by 5% in the first nine months. As in prior years, we expect a sequential step-up in the fourth quarter versus third quarter in operating expenses. Other operating income was $618 million for the first nine months, including $277 million in the third quarter. This includes the sale of Zoryve royalties for $100 million. We expect the other operating income in the second half of the year to be slightly higher than the first half. The core tax rate was 19% year to date, consistent with our full year expected range of 18%-22%. Core EPS grew by 14% in the first nine months. Next slide, please. Turning to cash flow and the balance sheet. Cash flow from operating activities was $10.9 billion in the first nine months, lower than in the comparative period. There are two principal factors behind that.

Aradhana SarinCFO

First, the prior year period benefited from the Lynparza milestone receipt in Q1 2025. Second, we have experienced working capital effects associated with the U.S. loss of exclusivity for Farxiga. As previously indicated, we expect these working capital effects to persist through the remainder of the year before normalizing. Capital expenditure was $2.3 billion in the period, and we now expect full-year CapEx to increase by low teens percentage compared to 2025. This is a change from prior indication, driven as a result of some project starts now moving into 2027. Deal-related payments totaled $4.3 billion in the first nine months. This includes the $600 million upfront payment for the Dizal collaboration, which closed during the third quarter, and other new deals during the year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day